<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment &amp; Growth Summit. David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs. Presentation Details Event: BIO Investment &amp; Growth Summit Date/Time: Monday, March 2, 2026 at 2:30 PM Location: Ballroom I, Salon C About NEK7 NEK7 is a critical regulator of inflammasome activation and a required component for assembly and activation of the NLRP3 inflammasome. Activation of this pathway can drive the release of proinflammatory cytokines, including IL-1β and IL-18, contributing to chronic inflammation across hematology, cardiometabolic, pain, and other inflammation-driven diseases. Targeting NEK7 offers a pathway-level approach to modulating NLRP3 inflammasome activity upstream, providing a differentiated strategy versus blocking individual downstream cytokines. About Halia Therapeutics Halia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies. Media Contact Taylor Avei Director of Business Development Halia Therapeutics [email protected] SOURCE Halia Therapeutics <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9TEE5ODc4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIwODM1UFJfTkVXU19VU1BSX19fX19MQTk4Nzg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9TEE5ODc4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIwODM1UFJfTkVXU19VU1BSX19fX19MQTk4Nzg4"/></div> </div></div>

ARKG

Halia Therapeutics, a clinical-stage biopharmaceutical company, announced its presentation at the BIO Investment & Growth Summit on March 2, 2026. CEO David Bearss will discuss the company's strategy, platform, and clinical programs. Halia focuses on developing first-in-class inflammasome inhibitors to address inflammation-driven diseases by targeting NEK7, a key regulator of inflammasome activation.

prnewswire

VG Health

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

VanEck Biotech ETF

Proshares UltraShort Nasdaq Biotech

08:35 ETHalia Therapeutics Announces Presentation at the BIO Investment & Growth Summit